Dysgerminoma of ovary

Summary

Dysgerminoma of ovary (MONDO:0003481) is a disease and 4 clinical trials. Top therapeutic interventions include imatinib and tremelimumab. A subtype of dysgerminoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	dysgerminoma of ovary
Mondo ID	MONDO:0003481
EFO	EFO:1000414
DOID	DOID:5511
ICD-11	208782658
NCIT	C8106
SNOMED CT	254874008
UMLS	C0346185
MedGen	83414
GARD	0023525
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	no

Also known as: dysgerminoma · dysgerminoma of ovary · dysgerminoma of the ovary · germ cell dysgerminoma of ovary · germ cell dysgerminoma of the ovary · ovarian dysgerminoma · ovarian germ cell dysgerminoma · ovary dysgerminoma (disease)

Data availability: 2 cell lines.

Disease family

This is a subtype of dysgerminoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant germ cell tumor › dysgerminoma › dysgerminoma of ovary

Related subtypes (1): pineal region dysgerminoma

Subtypes (1): pediatric ovarian dysgerminoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03158064	PHASE2	ACTIVE_NOT_RECRUITING	Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
NCT00042952	PHASE2	TERMINATED	Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer
NCT00204633	PHASE2	COMPLETED	Darbepoetin Alfa in Patients With Poor Prognosis Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)
NCT01080521	Not specified	COMPLETED	Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IMATINIB	4	1
TREMELIMUMAB	4	1